December 21, 2019
Validation of Arc and Ephexin5 as Novel Therapeutic Targets for the Treatment of Angelman Syndrome
$200,000 – 2-years While it has been appreciated for some time that loss-of-function mutations in the UBE3A gene are the primary causative factor for Angelman syndrome (AS), the precise mechanisms by which the loss of Ube3A in the nervous system […]
Read more